Venclexta (venetoclax) | Friends of Cancer Research

You are here

Venclexta (venetoclax)

Sponsor: 
Abbvie Inc.
Indication: 
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one prior therapy
Category: 
Year: 
2018
FDA Status: 
FDA Approval
Approval Date: 
Jun 8th
Approval Year: 
2018